chronic myeloproliferative disorder: A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008)
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
1236 |
4. Check minimum number of eventsNone |
1236 |
5. Include endpointsNone |
1236 |
6. Filter based on genotype QC (FinnGen only) |
1236 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- First used in FinnGen datafreeze
- DF8
Polycythaemia vera
based on the number of shared cases.
Similar with more cases:
Similar with less cases:
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 8645 | 4398 | 4141 |
| Only index persons | 6571 | 3383 | 3188 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.12 | 0.13 | 0.12 |
| Only index persons | 0.12 | 0.12 | 0.12 |
| Median age at first event (years) | |||
| Whole population | 67.45 | 69.26 | 65.58 |
| Only index persons | 67.11 | 69.04 | 65.06 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 1236 | 594 | 642 |
| Unadjusted period prevalence (%) | 0.24 | 0.20 | 0.28 |
| Median age at first event (years) | 65.55 | 64.99 | 66.07 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 1118
- Matched controls
- 11179
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
511.3
323.0
754
45
L01XX05
ATC
hydroxycarbamide; oral
648.3
323.0
687
27
9950/3-C42.1
ICD-O-3
Polycythemia vera of bone marrow
+∞
323.0
310
*
TPH00
NOMESCO Finland
Phlebotomy
1649.6
323.0
344
*
D45
ICD-10 Finland
Polycythaemia vera
4503599627370496.0
323.0
1091
*
SPAT1074
SPAT
Venesection
598.6
249.0
238
5
XW000
NOMESCO Finland
Bone marrow biopsy
34.1
226.5
300
119
D47.3
ICD-10 Finland
Essential (haemorrhagic) thrombocythaemia
66.4
167.8
193
35
D47.1
ICD-10 Finland
Chronic myeloproliferative disease
201.3
138.1
141
8
D75.2
ICD-10 Finland
Essential thrombocytosis
67.8
115.1
132
22
L03AB05
ATC
interferon alfa-2b; parenteral
+∞
112.4
106
*
B99
ICPC
Blood/lymph/spleen disease other
95.5
94.9
104
12
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
47.3
90.9
111
26
D75.1
ICD-10 Finland
Secondary polycythaemia
61.7
78.2
91
16
M04AA01
ATC
allopurinol; systemic
4.2
71.0
320
974
D75.9
ICD-10 Finland
Disease of blood and blood-forming organs, unspecified
83.9
70.0
78
10
L03AB04
ATC
interferon alfa-2a; parenteral
710.0
68.8
67
*
L01XX35
ATC
anagrelide; oral
128.1
67.7
72
6
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
64.2
61
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
218.5
60.7
62
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.3
57.6
244
686
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
56.7
54
*
9960/3-C42.1
ICD-O-3
Myeloproliferative neoplasm, NOS, of bone marrow
575.6
56.1
55
*
9961/3-C42.1
ICD-O-3
Primary myelofibrosis of bone marrow
152.7
55.4
58
*
174
Kela drug reimbursment
Ruxolitinib
520.5
50.8
50
*
374
Kela drug reimbursment
Ruxolitinib
476.7
46.6
46
*
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
49.0
46.5
56
12
L01XE18
ATC
[U] ruxolitinib; oral
+∞
39.8
38
*
212
Kela drug reimbursment
Gout
9.7
39.8
83
92
L01EJ01
ATC
ruxolitinib; oral
400.9
39.3
39
*
WW500
NOMESCO Finland
Blood transfusion
9.4
37.8
80
91
130
Kela drug reimbursment
Malignant tumour
+∞
37.7
36
*
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
4.1
37.5
157
425
D75.0
ICD-10 Finland
Familial erythrocytosis
85.1
37.0
41
5
116
Kela drug reimbursment
Prostate cancer
+∞
36.7
35
*
B74
ICPC
Malignant neoplasm blood other
357.9
35.1
35
*
9962/3-C42.1
ICD-O-3
Essential thrombocythemia of bone marrow
53.1
34.6
41
8
B28
ICPC
Limited function/disability (B)
29.9
34.5
46
16
H02AB02
ATC
dexamethasone; systemic
15.7
32.9
54
36
115
Kela drug reimbursment
Breast cancer
+∞
32.4
31
*
B01AB05
ATC
enoxaparin; parenteral
2.3
32.1
381
2039
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
30.3
29
*
XX7BT
NOMESCO Finland
Radioactive phosphorus therapy
159.2
29.8
31
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.1
29.3
539
3464
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
+∞
29.3
28
*
B04
ICPC
Blood symptom/complaint
25.2
28.0
39
16
2384A
ICD-9 Finland
Neoplasm of uncertain behaviour of other and unspecified sites and tissues, Polycythaemia vera
+∞
25.1
24
*
C44.32
ICD-10 Finland
Spinocellular carcinoma of the skin on another or unspecified part of the face
132.9
24.7
26
*
8090/3-C44.3
ICD-O-3
Basal cell carcinoma, NOS, of skin of other and unspecified parts of face
+∞
24.0
23
*
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
4.9
23.9
80
172
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
+∞
23.0
22
*
8090/3-C44.5
ICD-O-3
Basal cell carcinoma, NOS, of skin of trunk
+∞
21.9
21
*
TPH00
SPAT
NA
224.1
21.7
22
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
44.3
21.5
26
6
NEA10
NOMESCO Finland
Exploration of soft tissue of pelvis, percutaneous
42.5
20.5
25
6
C44.51
ICD-10 Finland
Basocellular carcinoma of the skin on the torso
49.0
20.2
24
5
WF002
NOMESCO Finland
Radical radiotherapy
36.5
19.9
25
7
C92.0
ICD-10 Finland
Acute myeloblastic leukaemia [AML]
+∞
19.8
19
*
R79.9
ICD-10 Finland
Abnormal finding of blood chemistry, unspecified
22.0
19.6
28
13
20899
ICD-8 Finland
Polycythaemia vera
+∞
18.8
18
*
B75
ICPC
Neoplasm blood benign/unspecified
193.1
18.6
19
*
L02AE02
ATC
leuprorelin; implant, parenteral
44.8
18.3
22
5
A04AA01
ATC
ondansetron; systemic, rectal
6.1
18.0
49
83
R50.9
ICD-10 Finland
Fever, unspecified
2.5
17.9
151
658
JN4BD
NOMESCO Finland
Extensive body CT
3.5
17.8
85
255
XX3DW
NOMESCO Finland
Time consuming IT work
3.8
17.8
78
218
C90.0
ICD-10 Finland
Multiple myeloma
+∞
17.8
17
*
L03AA04
ATC
NA
182.7
17.6
18
*
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
2.9
17.5
110
402
R79.8
ICD-10 Finland
Other specified abnormal findings of blood chemistry
17.3
17.4
27
16
Z51.5
ICD-10 Finland
Palliative care
5.3
17.0
52
102
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
16.7
16
*
L01AB01
ATC
busulfan; systemic
+∞
16.7
16
*
C64.88
ICD-10 Finland
Other malignant neoplasm of kidney, except renal pelvis
+∞
16.7
16
*
8070/3-C44.9
ICD-O-3
Squamous cell carcinoma, NOS, of skin, NOS
+∞
16.7
16
*
HAC20
NOMESCO Finland
Total mastectomy
91.4
16.6
18
*
HA003
NOMESCO Finland
Radiotherapy after partial ablation of mammary gland
172.4
16.5
17
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
172.4
16.5
17
*
I81
ICD-10 Finland
Portal vein thrombosis
23.4
16.5
23
10
ZX120
NOMESCO Finland
Intravenous
2.9
16.2
102
373
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
60.9
15.8
18
*
G04BE03
ATC
sildenafil; oral
33.9
15.8
20
6
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
+∞
15.7
15
*
C50.99
ICD-10 Finland
Breast, unspecified
+∞
15.7
15
*
D47.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue, unspecified
29.0
15.2
20
7
L02BG04
ATC
letrozole; oral
23.7
15.1
21
9
L57.0
ICD-10 Finland
Actinic keratosis
2.6
15.1
117
485
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.3
14.9
145
675
ZX112
NOMESCO Finland
Subcutaneous
12.6
14.9
26
21
ZZR00
NOMESCO Finland
Flap of skin
12.6
14.9
26
21
D73.5
ICD-10 Finland
Infarction of spleen
57.5
14.8
17
*
A03FA01
ATC
metoclopramide; systemic, rectal
2.3
14.7
144
675
B01AA03
ATC
warfarin; systemic
1.8
14.6
304
1918
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
14.6
14
*
9861/3-C42.1
ICD-O-3
Acute myeloid leukemia, NOS, of bone marrow
+∞
14.6
14
*
C91.1
ICD-10 Finland
Chronic lymphocytic leukaemia of B-cell type
151.9
14.5
15
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
151.9
14.5
15
*
Y77
ICPC
Malignant neoplasm prostate
151.9
14.5
15
*
A04AA02
ATC
granisetron; systemic, transdermal
36.5
14.5
18
5
379
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the long-term prevention of recurrent deep veinthrombosis and pulmonary embolism
4.6
14.1
48
107
D72.8
ICD-10 Finland
Other specified disorders of white blood cells
12.9
13.9
24
19
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
2.6
13.9
103
414
NK6AN
NOMESCO Finland
Total body bone isotope imaging
30.4
13.9
18
6
JN4AD
NOMESCO Finland
Body CT examination
3.7
13.9
61
172
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
1.7
13.7
333
2198
L03AA13
ATC
pegfilgrastim; parenteral
+∞
13.6
13
*
PJD52
NOMESCO Finland
Block dissection of axillary lymph nodes
+∞
13.6
13
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
13.6
13
*
C50.40
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, no histological veryfication
+∞
13.6
13
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
2.3
13.5
129
597
PH_2
NOMESCO Finland
Other procedures on veins
141.6
13.5
14
*
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
1.8
13.3
258
1582
WF003
NOMESCO Finland
Adjuvant radiotherapy
32.4
12.6
16
5
D47.0
ICD-10 Finland
Histiocytic and mast cell tumours of uncertain and unknown behaviour
+∞
12.5
12
*
C73.91
ICD-10 Finland
Papillary carcinoma of the thyroid gland (thyroid gland)
+∞
12.5
12
*
I26.9
ICD-10 Finland
Pulmonary embolism without mention of acute cor pulmonale
2.9
12.3
77
282
D04.3
ICD-10 Finland
Carcinoma in situ: Skin of other and unspecified parts of face
6.7
12.1
30
46
N02AA05
ATC
oxycodone; systemic
2.1
12.0
145
744
TPH04
NOMESCO Finland
Cathetrisation of vein
1.8
11.9
220
1321
D75.8
ICD-10 Finland
Other specified diseases of blood and blood-forming organs
47.2
11.9
14
*
L03AA02
ATC
filgrastim; parenteral
30.4
11.7
15
5
C44.21
ICD-10 Finland
Basocellular carcinoma of the skin of the outer ear and the outer ear canal
+∞
11.5
11
*
C50
ICD-10 Finland
Malignant neoplasm of breast
+∞
11.5
11
*
C20.91
ICD-10 Finland
Malignant tumor of the rectum invasive carcinoma
+∞
11.5
11
*
XW4XT
NOMESCO Finland
Biopsy of other inner organ with radiological guidance guidance
121.2
11.4
12
*
HA1AA
NOMESCO Finland
X-ray mammography
4.2
11.3
42
103
B01AB10
ATC
tinzaparin; parenteral
3.0
11.1
64
223
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
4.9
11.0
35
73
I85.9
ICD-10 Finland
Oesophageal varices without bleeding
9.3
11.0
22
24
JN4CD
NOMESCO Finland
Very extensive body CT
5.0
11.0
34
69
S97
ICPC
Chronic ulcer skin
2.6
10.8
79
317
Z01.8
ICD-10 Finland
Other specified special examinations
1.8
10.8
228
1426
R71
ICD-10 Finland
Abnormality of red blood cells
18.0
10.7
16
9
HAB40
NOMESCO Finland
Wedge excision of mammary gland
13.0
10.7
18
14
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
60.6
10.6
12
*
B03XA02
ATC
darbepoetin alfa; parenteral
5.4
10.6
31
59
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
6.6
10.5
26
40
L02BB03
ATC
bicalutamide; oral
111.0
10.4
11
*
8140/3-C20.9
ICD-O-3
Adenocarcinoma, NOS, of rectum, NOS
+∞
10.4
10
*
KEC00
NOMESCO Finland
Retropubic radical prostatectomy
+∞
10.4
10
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
10.4
10
*
C83.31
ICD-10 Finland
Diffuse lymphoma with large B cells
+∞
10.4
10
*
C50.81
ICD-10 Finland
Overall malignant tumor of the mammary gland, ductal tumor
+∞
10.4
10
*
C54.11
ICD-10 Finland
Adenocarcinoma of the endometrium
+∞
10.4
10
*
I80.29
ICD-10 Finland
Phlebitis and thrombophlebitis of other deep vessels of lower extremities
3.3
10.4
52
164
Z03.9
ICD-10 Finland
Observation for suspected disease or condition, unspecified
1.8
10.3
187
1112
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
2.6
10.0
74
299
XQ848
NOMESCO Finland
Dermatological photography
4.6
9.9
33
73
THW99
NOMESCO Finland
Other minor procedure in surgery of mammary gland
26.3
9.8
13
5
D48.5
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Skin
3.0
9.6
53
180
K99
ICPC
Cardiovascular disease other
3.2
9.6
50
163
L02BA01
ATC
tamoxifen; oral
100.8
9.4
10
*
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
100.8
9.4
10
*
D05.1
ICD-10 Finland
Intraductal carcinoma in situ
100.8
9.4
10
*
8380/3-C54.1
ICD-O-3
Endometrioid adenocarcinoma, NOS, of endometrium
+∞
9.4
9
*
166
Kela drug reimbursment
Dalteparin and tinzaparin (treatment for more than 6 months)
+∞
9.4
9
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
+∞
9.4
9
*
C67.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of bladder
+∞
9.4
9
*
D58.2
ICD-10 Finland
Other haemoglobinopathies
+∞
9.4
9
*
XPX99
NOMESCO Finland
Other diagnostic examination of periferal vessel
2.2
9.3
97
468
SPAT1148
SPAT
Treatment of chronic ulcer or burn
1.8
9.2
164
971
T81.0
ICD-10 Finland
Haemorrhage and haematoma complicating a procedure, not elsewhere classified
2.4
9.1
74
315
TNE20
NOMESCO Finland
Bone marrow aspiration, pelvis
24.2
8.9
12
5
C44.41
ICD-10 Finland
Basocellular carcinoma of the skin of the scalp and neck
50.4
8.7
10
*
R16.1
ICD-10 Finland
Splenomegaly, not elsewhere classified
50.4
8.7
10
*
L98.4
ICD-10 Finland
Chronic ulcer of skin, not elsewhere classified
4.2
8.6
31
75
M10.9
ICD-10 Finland
Gout, unspecified
2.2
8.6
91
440
L02BG03
ATC
anastrozole; oral
90.7
8.4
9
*
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
90.7
8.4
9
*
I82.0
ICD-10 Finland
Budd-Chiari syndrome
90.7
8.4
9
*
R04.0
ICD-10 Finland
Epistaxis
2.1
8.4
97
490
WB203
NOMESCO Finland
Simple adjuvant hormone therapy of malignancy
+∞
8.3
8
*
8090/3-C44.4
ICD-O-3
Basal cell carcinoma, NOS, of skin of scalp and neck
+∞
8.3
8
*
8260/3-C73.9
ICD-O-3
Papillary adenocarcinoma, NOS, of thyroid gland
+∞
8.3
8
*
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
2.1
8.3
92
456
I26.0
ICD-10 Finland
Pulmonary embolism with mention of acute cor pulmonale
4.2
8.3
30
73
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
1.6
8.3
243
1657
D46.7
ICD-10 Finland
Other myelodysplastic syndromes
11.8
8.1
14
12
QBE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin of trunk
2.6
8.0
55
215
J01DB01
ATC
cefalexin; oral
1.5
8.0
809
7143
C03DA01
ATC
spironolactone; oral
1.8
7.9
143
848
QAA25
NOMESCO Finland
Destruction of lesion of head or neck
4.0
7.9
30
77
A46
ICD-10 Finland
Erysipelas
1.7
7.8
165
1027
JN3AD
NOMESCO Finland
Abdominal CT examination
2.2
7.8
74
343
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
1.8
7.7
130
754
B86
ICPC
OTHER HAEMATOLOGICAL ABNORMALITY
45.3
7.7
9
*
PJD42
NOMESCO Finland
Excision of axillary lymph nodes
45.3
7.7
9
*
Z08.0
ICD-10 Finland
Follow-up examination after surgery for malignant neoplasm
18.5
7.6
11
6
D68.8
ICD-10 Finland
Other specified coagulation defects
7.2
7.5
17
24
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
1.7
7.5
154
952
C67.9
ICD-10 Finland
Malignant neoplasm: Bladder, unspecified
80.6
7.4
8
*
8312/3-C64.9
ICD-O-3
Renal cell carcinoma, NOS, of kidney, NOS
+∞
7.3
7
*
C34.90
ICD-10 Finland
Malignant tumor in unspecified location in bronchus and lung without histology
+∞
7.3
7
*
C44.39
ICD-10 Finland
Malignant tumor of the skin on another or unspecified part of the face other or unspecified histology
+∞
7.3
7
*
B01AC14
ATC
[U] anagrelide; oral
+∞
7.3
7
*
PJ5AN
NOMESCO Finland
Localisation of sentinell lymphnode with isotope imaging
+∞
7.3
7
*
B59
ICPC
Blood and Immunity, Other therap proced/minor surg NEC
+∞
7.3
7
*
8090/3-C44.1
ICD-O-3
Basal cell carcinoma, NOS, of eyelid
+∞
7.3
7
*
L01BC06
ATC
capecitabine; oral
+∞
7.3
7
*
C44.22
ICD-10 Finland
Spinocellular carcinoma of the skin of the outer ear and the outer ear canal
+∞
7.3
7
*
KE3AT
NOMESCO Finland
Transrectal gold marker implantation in prostate under ultrasound guidance
+∞
7.3
7
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
7.3
7
*
128
Kela drug reimbursment
Cancers of female genital organs
+∞
7.3
7
*
8070/3-C44.3
ICD-O-3
Squamous cell carcinoma, NOS, of skin of other and unspecified parts of face
+∞
7.3
7
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
7.3
7
*
I63.9
ICD-10 Finland
Cerebral infarction, unspecified
1.7
7.2
147
904
TQW99
NOMESCO Finland
Other minor procedure on skin
2.8
7.2
44
163
Z94.8
ICD-10 Finland
Other transplanted organ and tissue status
30.2
7.2
9
*
308
Kela drug reimbursment
Alprostadil, sildenafil and combination product containing aviptadil and phentolamine
20.2
7.1
10
5
C07AB07
ATC
bisoprolol; oral
1.4
7.1
556
4618
TPW99
NOMESCO Finland
Other minor surgical procedure on peripheral vessel or lymphatic system
6.6
7.1
17
26
A07AA02
ATC
nystatin; oral
2.2
7.1
70
331
JN3BD
NOMESCO Finland
Extensive abdominal CT
1.9
7.1
95
509
D47.2
ICD-10 Finland
Monoclonal gammopathy of undetermined significance (MGUS)
5.0
7.0
21
43
K93
ICPC
Pulmonary embolism
5.2
7.0
20
39
ZXC20
NOMESCO Finland
Use of chemical agents
4.7
6.9
22
48
SPAT1088
SPAT
Blood transfusion
13.9
6.9
11
8
I50.9
ICD-10 Finland
Heart failure, unspecified
1.6
6.8
186
1241
PH1AE
NOMESCO Finland
Ultrasound examination of upper extremity veins
6.1
6.8
17
28
JN1DG
NOMESCO Finland
Very extensive MRI examination of upper part of abdomen with high intensity magnet
5.7
6.8
18
32
A79
ICPC
Malignancy NOS
40.3
6.8
8
*
K29
ICPC
Cardiovascular sympt/complt other
2.3
6.7
60
273
KAC11
NOMESCO Finland
Total nephrectomy with capsule, transcutaneous
22.7
6.7
9
*
QXA25
NOMESCO Finland
Destruction of lesion of skin, site unspecified
3.4
6.7
30
90
D69.6
ICD-10 Finland
Thrombocytopenia, unspecified
4.2
6.6
23
55
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
3.6
6.6
28
80
L71.9
ICD-10 Finland
Rosacea, unspecified
3.7
6.6
27
75
QAA05
NOMESCO Finland
Incision for biopsy of skin of head or neck
4.2
6.5
23
56
C03CA01
ATC
furosemide; systemic
1.4
6.5
360
2796
R06.0
ICD-10 Finland
Dyspnoea
1.5
6.5
259
1885
ZXC50
NOMESCO Finland
Cryotherapy
3.2
6.5
31
98
XX1XT
NOMESCO Finland
Other puncture with other radiological guidance
70.2
6.4
7
*
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
70.2
6.4
7
*
X76
ICPC
Malignant neoplasm breast female
70.2
6.4
7
*
R18
ICD-10 Finland
Ascites
4.9
6.4
19
39
UGC12
NOMESCO Finland
Flexible bronchoscopy
2.0
6.3
73
370
PJ2AE
NOMESCO Finland
Lymphnode ultrasound examination
11.1
6.3
11
10
N02AX02
ATC
tramadol; systemic, rectal
1.4
6.3
406
3242
G45.9
ICD-10 Finland
Transient cerebral ischaemic attack, unspecified
1.8
6.3
102
587
C50.51
ICD-10 Finland
Malignant tumor of the lower outer quadrant of the mammary gland, ductal tumor
+∞
6.3
6
*
C20.90
ICD-10 Finland
Malignant tumor of the rectum without histology
+∞
6.3
6
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
6.3
6
*
C34.12
ICD-10 Finland
Malignant tumor of the anterior, bronchial or pulmonary adenocarcinoma
+∞
6.3
6
*
8500/2-C50.9
ICD-O-3
Intraductal carcinoma, noninfiltrating, NOS, of breast, NOS
+∞
6.3
6
*
C34.99
ICD-10 Finland
Malignant tumor in unspecified localization in bronchial and pulmonary other or unspecified histology
+∞
6.3
6
*
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
6.3
6
*
C02KX04
ATC
macitentan; oral
+∞
6.3
6
*
C34.3
ICD-10 Finland
Malignant neoplasm: Lower lobe, bronchus or lung
+∞
6.3
6
*
8310/3-C64.9
ICD-O-3
Clear cell adenocarcinoma, NOS, of kidney, NOS
+∞
6.3
6
*
ZX080
NOMESCO Finland
Image guided radiotherapy
+∞
6.3
6
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
6.3
6
*
C50.49
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, other or undeterminated histology
+∞
6.3
6
*
C43.52
ICD-10 Finland
Malignant melanoma on the torso: 'superficial spreading' type
+∞
6.3
6
*
XZZ00
NOMESCO Finland
Active surveillance of a diagnosed cancer
+∞
6.3
6
*
8140/3-C34.1
ICD-O-3
Adenocarcinoma, NOS, of upper lobe, lung
+∞
6.3
6
*
C67.2
ICD-10 Finland
Malignant neoplasm: Lateral wall of bladder
+∞
6.3
6
*
C50.90
ICD-10 Finland
Malignant tumor in other or unspecified location in mammary gland without histology
+∞
6.3
6
*
8720/3-C44.9
ICD-O-3
Malignant melanoma, NOS, of skin, NOS
+∞
6.3
6
*
D69.1
ICD-10 Finland
Qualitative platelet defects
26.8
6.2
8
*
T14.5
ICD-10 Finland
Injury of blood vessel(s) of unspecified body region
7.1
6.2
14
20
R58
ICD-10 Finland
Haemorrhage, not elsewhere classified
3.8
6.2
24
64
N02BE01
ATC
paracetamol; systemic, rectal
1.4
6.1
878
8014
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
376
106
50.54
307.65
1.1
1.0
—
—
—
0
0
243
122
24.55
307.65
1.6
1.5
—
—
—
0
0
439
163
41.22
307.65
1.3
1.2
18.5
21.8
u/l
0.20
333
142
817
958
23.21
307.65
10.1
2.6
292.9
237.4
u/l
16.21
805
899
435
892
6.98
217.75
3.9
2.2
88.2
68.2
e9/l
19.62
320
689
506
1210
6.39
215.64
4.2
2.0
2.0
1.8
%
3.94
451
1062
756
2621
5.85
209.82
5.2
2.4
2297.1
7637.1
umol/l
3.65
714
2215
343
631
7.14
188.97
10.4
3.6
0.8
0.6
%
0.44
141
108
953
4333
6.24
182.70
18.3
5.5
21.6
26.9
%
40.26
928
3969
943
4297
6.04
178.83
16.5
5.4
64.9
57.9
%
49.45
916
3955
142
92
17.31
166.69
8.4
2.9
1.4
1.3
%
0.13
101
66
998
5085
6.00
155.97
23.1
6.0
6.5
4.3
e9/l
26.36
941
4339
897
4679
4.34
122.72
10.3
3.8
13.3
12.1
umol/l
2.55
879
4357
410
1304
4.21
114.34
2.8
2.5
18.5
22.7
%
5.56
356
1091
414
1401
3.94
104.61
2.6
2.4
2.6
2.3
g/l
17.47
391
1288
151
219
7.72
101.13
3.0
2.2
3.1
3.4
g/l
2.02
143
203
430
1539
3.75
99.34
2.7
2.4
11.1
12.9
umol/l
4.46
406
1404
91
70
13.95
96.47
9.3
3.0
70.9
52.5
%
5.19
47
45
676
3837
2.68
62.63
3.7
2.7
117.3
136.1
ug/l
0.96
635
3464
118
225
5.69
59.87
2.6
2.0
91.4
86.4
%
1.43
105
216
95
146
6.97
59.80
4.8
3.0
65.9
58.6
%
3.98
95
146
170
461
4.12
56.21
1.8
1.6
1.0
1.5
g/l
13.84
149
403
1014
7335
3.13
54.11
16.5
5.3
88.7
76.5
u/l
10.83
993
6743
776
5002
2.48
50.80
8.1
5.6
1.2
1.2
mmol/l
0.36
653
4212
86
143
6.39
50.10
3.6
2.9
6.0
4.4
e9/l
3.02
86
143
103
230
4.79
43.44
2.0
1.5
—
—
—
0
0
94
201
4.98
41.72
3.1
2.2
171.0
200.5
%
2.28
88
190
70
127
5.78
37.23
5.6
5.1
505.7
473.8
iu/ml
—
6
18
639
4159
2.11
35.84
6.4
3.7
35.5
35.3
g/l
0.29
604
3807
34
26
13.42
35.80
7.0
2.0
—
—
—
0
0
679
4530
2.11
35.55
7.4
5.2
1.2
1.2
mmol/l
0.92
620
3984
226
955
2.67
35.20
5.3
2.2
7.6
8.4
umol/l
0.39
203
820
450
2597
2.15
34.26
2.4
2.2
8.1
2.9
mg/l
26.83
385
2167
368
1997
2.20
32.46
2.2
1.6
1.2
1.3
mg/l
0.50
288
1539
800
5885
2.02
29.60
5.8
4.5
6.6
6.9
mmol/l
3.30
771
5511
278
1433
2.21
27.27
3.8
2.5
0.8
0.8
mmol/l
0.04
260
1302
283
1546
2.08
23.53
3.1
1.9
33.2
30.0
s
7.84
264
1488
249
1296
2.15
23.51
5.4
4.7
1.1
1.0
mmol/l
2.15
234
1180
126
519
2.59
20.19
2.8
1.4
20.8
3.8
ug/l
0.49
100
391
158
738
2.31
19.22
2.0
1.9
0.2
0.2
g/l
0.10
147
660
50
120
4.30
19.21
2.1
1.5
—
—
—
0
0
134
589
2.43
18.69
2.3
2.1
10.7
10.9
g/l
0.17
119
533
30
47
6.52
18.43
1.1
1.3
—
—
—
0
0
30
47
6.52
18.43
1.1
1.3
—
—
—
0
0
62
180
3.57
18.30
2.0
1.4
—
—
—
0
0
83
296
2.93
17.51
2.7
1.5
1.4
1.2
ratio
—
7
24
23
8
29.26
17.45
1.1
1.0
—
—
—
0
0
84
306
2.87
17.05
2.7
1.5
30.4
35.6
mg/l
0.76
72
242
164
824
2.14
16.60
2.8
1.6
66.3
66.9
g/l
0.52
155
733
83
305
2.85
16.58
2.7
1.5
83.7
45.2
mg/l
0.43
70
241
58
174
3.45
16.30
2.2
1.4
—
—
—
0
0
18
18
10.13
15.83
1.4
1.1
64.0
82.4
%
—
10
8
18
18
10.13
15.83
1.4
1.1
67.3
87.1
%
—
10
8
166
863
2.07
15.32
6.3
6.0
10.1
10.7
mmol/l
0.59
157
809
14
10
14.15
15.06
1.1
1.8
—
—
—
0
0
96
403
2.50
14.75
2.4
1.7
1.2
1.6
ug/l
0.39
83
351
873
7303
1.67
14.46
5.1
4.2
8.6
12.9
mm/h
17.85
824
6683
18
5
36.49
14.46
1.1
1.0
—
—
—
0
0
272
1697
1.77
14.35
2.1
1.8
—
—
—
0
0
150
775
2.06
14.03
3.0
2.8
1.2
1.2
mmol/l
2.05
124
645
21
31
6.87
13.61
2.6
1.1
—
—
—
0
0
21
31
6.87
13.61
2.6
1.1
—
—
—
0
0
21
31
6.87
13.61
2.6
1.1
—
—
—
0
0
21
31
6.87
13.61
2.6
1.1
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
79
315
2.61
13.50
4.6
2.6
0.4
0.4
u/ml
0.01
49
185
543
4100
1.58
13.44
6.6
3.6
—
—
—
0
0
58
198
3.02
13.24
1.2
1.3
—
—
—
0
0
592
4588
1.56
12.89
2.3
2.1
87.9
94.3
pmol/l
3.02
395
2257
312
2092
1.66
12.44
5.2
2.1
—
—
—
0
0
383
2717
1.59
12.09
1.8
1.5
18.4
20.8
nmol/l
2.39
343
2244
16
21
7.71
11.44
3.1
1.1
—
—
—
0
0
16
21
7.71
11.44
3.1
1.1
—
—
—
0
0
16
21
7.71
11.44
3.1
1.1
—
—
—
0
0
436
3219
1.55
11.43
3.3
2.1
2.3
2.4
mmol/l
2.00
375
2625
127
674
1.99
10.98
2.2
1.5
—
—
—
0
0
409
3004
1.54
10.85
2.9
2.3
52.5
57.5
u/l
2.55
373
2744
35
99
3.61
10.80
1.0
1.1
—
—
—
0
0
27
65
4.22
10.39
2.4
1.2
—
—
—
0
0
27
65
4.22
10.39
2.4
1.2
—
—
—
0
0
27
65
4.22
10.39
2.4
1.2
—
—
—
0
0
459
3488
1.50
10.24
3.8
3.1
—
—
—
0
0
36
108
3.40
10.18
1.4
1.4
—
—
—
0
0
20
39
5.20
9.85
3.0
1.5
6278.6
984.3
e6/l
—
8
16
381
2812
1.51
9.67
4.8
2.6
32.5
33.8
u/l
0.36
364
2657
29
78
3.78
9.63
1.8
1.6
—
—
—
0
0
28
75
3.80
9.36
2.5
1.3
—
—
—
0
0
20
41
4.94
9.33
1.6
2.7
1229.8
1155.5
u/ml
0.06
20
41
41
141
2.97
9.30
1.5
1.4
—
—
—
0
0
459
3541
1.47
9.28
3.7
3.0
2041.8
1613.3
ng/l
1.08
401
3030
39
132
3.02
9.10
1.2
1.1
—
—
—
0
0
363
2681
1.50
9.08
3.6
3.0
0.5
0.4
e6/l
0.14
281
2036
14
9
15.71
9.04
3.4
1.0
44.2
17.4
u/ml
—
14
9
33
102
3.30
8.94
1.1
1.1
2.8
1.7
u/ml
0.55
12
27
691
5796
1.44
8.76
4.0
3.0
63.5
49.4
u/l
3.18
651
5277
83
413
2.08
8.58
2.4
1.7
—
—
—
0
0
290
2073
1.52
8.39
3.0
2.4
3.8
5.5
e6/l
2.39
256
1801
24
63
3.87
8.26
1.3
1.1
—
—
—
0
0
28
82
3.47
8.25
2.5
1.3
—
—
—
0
0
1047
9579
1.61
8.21
28.6
13.8
18.9
24.5
mg/l
9.16
925
7519
521
4186
1.42
8.19
4.7
4.0
55.2
62.3
ng/l
0.12
416
3114
18
38
4.79
8.13
2.6
1.9
2.2
3.6
nmol/l
1.40
18
38
31
99
3.19
7.99
1.1
1.2
3.2
6.1
u/ml
0.63
18
45
109
615
1.85
7.85
4.3
3.4
2.4
1.9
mmol/l
0.51
78
452
114
653
1.82
7.82
4.2
3.5
5.3
5.2
kpa
0.39
104
603
136
823
1.73
7.74
2.1
1.7
409.7
364.8
nmol/l
1.33
127
732
158
999
1.67
7.65
4.1
3.2
—
—
—
0
0
76
384
2.04
7.56
1.9
1.6
—
—
—
0
0
496
4029
1.39
7.00
2.4
2.3
76.9
79.1
nmol/l
0.92
446
3471
130
800
1.70
6.97
3.7
2.5
53.3
63.0
ml/min/173m2
3.38
84
327
30
103
2.96
6.88
1.7
1.4
—
—
—
0
0
47
204
2.36
6.81
2.3
1.8
102.3
74.5
u/ml
0.12
36
157
37
144
2.62
6.74
1.1
1.3
—
—
—
0
0
10
14
7.19
6.70
1.1
1.3
—
—
—
0
0
33
123
2.73
6.54
1.2
1.1
380.9
294.3
u/ml
0.57
19
65
72
378
1.96
6.47
2.8
1.4
3.3
3.1
g/l
0.55
55
287
77
414
1.92
6.46
2.7
1.4
—
—
—
0
0
77
414
1.92
6.46
2.7
1.4
3.4
3.9
g/l
2.47
55
284
77
414
1.92
6.46
2.7
1.4
6.8
7.5
g/l
3.28
56
292
21
60
3.54
6.45
2.1
1.6
—
—
—
0
0
73
387
1.94
6.38
2.8
1.4
10.9
10.6
g/l
0.18
59
319
569
4773
1.36
6.38
6.0
5.1
0.0
0.0
estimate
0.00
154
785
30
108
2.82
6.35
1.4
1.4
—
—
—
0
0
567
4759
1.35
6.31
4.3
3.8
0.0
0.0
estimate
0.00
162
791
13
26
5.04
6.23
1.5
1.3
—
—
—
0
0
65
335
1.99
6.17
3.0
1.4
1.1
0.5
g/l
0.68
55
282
59
294
2.06
6.14
2.9
1.4
0.0
0.0
g/l
0.59
53
265
41
176
2.38
6.12
1.4
1.5
—
—
—
0
0
11
19
5.83
6.11
1.3
1.2
—
—
—
0
0
24
78
3.12
6.06
1.1
1.2
52.2
55.8
u/l
0.14
16
52
572
4830
1.34
6.02
4.4
3.8
0.0
0.0
estimate
0.50
156
772
295
2244
1.41
5.96
1.8
1.8
1033.0
1174.7
nmol/l
1.91
231
1670
254
1887
1.44
5.85
3.5
2.2
2.4
2.5
mmol/l
0.17
224
1606
44
199
2.26
5.84
2.8
2.4
17.4
16.4
%
0.43
21
100
32
125
2.60
5.82
1.5
1.3
—
—
—
0
0
32
127
2.56
5.65
1.3
1.3
—
—
—
0
0
734
6471
1.33
5.57
5.4
4.6
14.9
2073.3
e6/l
—
7
102
213
1559
1.44
5.28
38.5
28.9
1.6
1.4
inr
0.73
33
211
54
277
1.99
5.23
3.1
1.4
0.0
0.0
g/l
0.00
49
252
106
668
1.64
5.22
1.8
1.6
—
—
—
0
0
443
3660
1.33
5.20
4.6
4.0
—
—
—
0
0
14
35
4.03
5.17
1.2
1.3
—
—
—
0
0
57
301
1.94
5.09
1.4
1.2
—
—
—
0
0
54
281
1.96
5.04
3.1
1.4
0.0
0.0
g/l
0.00
49
253
170
1203
1.48
5.01
2.0
1.8
—
—
—
0
0
60
325
1.89
4.98
2.9
3.1
—
—
—
0
0
978
9063
1.38
4.95
27.6
12.8
73.6
74.8
ml/min/173m2
1.06
873
7269
78
460
1.74
4.92
2.7
2.9
4.3
4.4
pmol/l
0.81
66
390
11
24
4.62
4.78
1.1
1.3
—
—
—
0
0
59
323
1.87
4.75
2.9
1.4
38.5
37.5
g/l
0.56
52
263
18
58
3.13
4.65
1.5
1.5
—
—
—
0
0
12
29
4.17
4.63
2.6
2.9
—
—
—
0
0
167
1197
1.46
4.61
5.9
7.1
1.0
1.3
mmol/l
0.36
123
923
167
1197
1.46
4.61
5.7
7.1
4.9
5.1
kpa
1.25
158
1146
167
1197
1.46
4.61
5.7
7.1
10.8
11.5
kpa
1.01
158
1145
7
5
14.07
4.58
1.0
1.8
—
—
—
0
0
20
70
2.89
4.50
1.1
1.1
—
—
—
0
0
27
113
2.42
4.33
1.0
1.1
—
—
—
0
0
49
261
1.91
4.31
1.4
1.6
1.1
0.1
iu/ml
—
9
60
321
2592
1.32
4.29
4.5
4.0
0.0
0.0
estimate
0.50
152
763
7
6
11.72
4.28
1.1
1.2
—
—
—
0
0
166
1208
1.43
4.23
2.0
1.8
—
—
—
0
0
118
807
1.51
4.12
2.2
2.1
33.9
39.9
u/l
0.45
97
656
992
9301
1.34
3.98
5.3
4.3
1.3
1.3
mmol/l
0.97
940
8344
842
7724
1.28
3.98
42.4
16.6
16.7
13.7
%
121.32
835
7488
142
1022
1.44
3.85
4.1
3.1
1.7
2.1
mmol/l
0.77
115
817
29
134
2.19
3.75
1.1
1.3
0.6
0.7
nmol/l
0.42
29
125
39
203
1.95
3.71
1.3
1.3
—
—
—
0
0
38
196
1.97
3.70
2.3
2.9
30.1
35.6
umol/l
0.91
31
169
66
405
1.67
3.67
4.9
3.7
24.4
24.9
mmol/l
0.63
59
368
9
16
5.66
3.66
5.4
1.1
—
—
—
0
0
22
92
2.42
3.57
2.5
2.3
—
—
—
0
0
7
9
7.81
3.56
1.1
1.0
—
—
—
0
0
117
831
1.45
3.42
3.5
3.6
89.8
93.0
ng/l
0.16
100
711
7
10
7.03
3.36
1.3
1.1
—
—
—
0
0
22
95
2.34
3.35
1.1
1.6
21145.6
95326.8
e6/l
—
9
55
43
240
1.82
3.34
2.3
2.1
13.6
12.0
mg/l
0.48
37
221
13
43
3.04
3.25
1.0
1.1
—
—
—
0
0
197
1541
1.33
3.23
3.6
2.8
1.5
2.7
e6/l
2.84
113
842
7
11
6.39
3.18
2.7
4.1
—
—
—
0
0
53
321
1.68
3.13
1.2
1.2
0.2
0.5
u/ml
—
5
29
12
39
3.10
3.09
1.4
1.5
—
—
—
0
0
12
39
3.10
3.09
1.4
1.5
—
—
—
0
0
5
5
10.03
2.98
1.0
1.4
—
—
—
0
0
23
107
2.17
2.98
1.0
1.6
2864.1
1706.2
e6/l
0.36
12
79
7
14
5.02
2.73
1.7
1.0
—
—
—
0
0
7
14
5.02
2.73
1.7
1.0
—
—
—
0
0
9
24
3.77
2.67
1.6
2.2
1.2
1.2
mmol/l
—
9
24
82
573
1.46
2.65
3.5
2.2
13.6
14.9
nmol/l
0.70
76
500
87
615
1.45
2.65
1.8
1.5
—
—
—
0
0
207
1676
1.28
2.64
3.4
2.6
0.6
1.5
e6/l
2.96
121
973
13
49
2.67
2.62
1.4
1.4
—
—
—
0
0
390
3399
1.22
2.56
2.3
2.2
153.4
232.1
u/l
1.61
360
3172
36
208
1.75
2.56
1.2
1.1
—
—
—
0
0
945
8954
1.24
2.55
5.3
4.7
2.1
2.1
mu/l
0.11
897
8046
791
7372
1.20
2.50
4.2
3.8
15.0
15.0
pmol/l
0.05
732
6589
40
241
1.68
2.46
1.8
1.7
—
—
—
0
0
128
982
1.34
2.42
6.4
7.8
127.2
121.4
g/l
1.67
122
950
32
183
1.77
2.37
1.4
1.6
—
—
—
0
0
5
8
6.27
2.37
1.4
1.6
—
—
—
0
0
16
71
2.27
2.35
1.0
1.0
—
—
—
0
0
12
47
2.57
2.27
1.0
1.0
—
—
—
0
0
58
391
1.51
2.27
2.2
1.9
40.1
39.3
u/l
0.10
49
330
7
18
3.90
2.25
1.1
1.1
—
—
—
0
0
1064
10255
1.27
2.23
30.4
16.9
139.4
139.7
mmol/l
3.57
1050
9959
12
48
2.51
2.19
2.1
1.9
17.3
17.9
nmol/l
0.12
12
38
36
572
0.62
2.17
2.2
1.8
—
—
—
0
0
44
282
1.58
2.16
4.0
3.4
0.8
0.8
nmol/l
0.17
32
223
255
2164
1.22
2.16
3.8
4.1
143.0
484.2
ng/l
3.30
199
1826
22
116
1.91
2.11
2.3
1.2
—
—
—
0
0
22
116
1.91
2.11
2.3
1.2
—
—
—
0
0
65
456
1.45
2.11
5.2
5.5
1.9
1.6
%
0.88
59
437
21
110
1.92
2.06
1.2
1.1
—
—
—
0
0
13
56
2.34
2.05
1.5
1.2
—
—
—
0
0
13
56
2.34
2.05
1.9
2.3
—
—
—
0
0
12
50
2.41
2.03
1.6
1.5
1.7
10.2
u/l
—
7
23
36
225
1.62
1.98
2.0
2.1
140.0
131.4
g/l
0.71
28
167
6
16
3.76
1.93
2.0
1.4
—
—
—
0
0
1063
10280
1.24
1.92
32.1
17.0
4.0
4.0
mmol/l
5.45
1049
9964
16
78
2.07
1.91
1.1
1.1
—
—
—
0
0
532
4864
1.16
1.90
2.5
2.4
—
—
—
0
0
21
114
1.86
1.88
2.3
1.2
—
—
—
0
0
10
40
2.51
1.84
1.7
1.2
—
—
—
0
0
10
40
2.51
1.84
1.7
1.2
—
—
—
0
0
5
12
4.18
1.82
1.0
1.2
—
—
—
0
0
21
116
1.82
1.79
2.3
1.2
—
—
—
0
0
997
9601
1.20
1.76
5.7
4.8
1.2
1.4
mmol/l
42.31
947
8697
16
81
1.99
1.75
1.1
1.2
—
—
—
0
0
883
8423
1.17
1.72
35.6
15.5
40.6
39.4
%
1.93
527
5393
12
55
2.19
1.67
1.6
1.2
—
—
—
0
0
1005
9701
1.19
1.64
5.8
4.8
4.0
4.5
mmol/l
53.59
962
8851
91
708
1.31
1.63
9.6
7.3
23.7
24.5
mmol/l
0.90
84
663
20
113
1.78
1.61
2.4
1.2
—
—
—
0
0
10
43
2.34
1.60
1.3
1.2
—
—
—
0
0
130
1061
1.25
1.60
1.3
1.4
—
—
—
0
0
7
26
2.70
1.58
2.7
1.4
—
—
—
0
0
20
114
1.77
1.57
2.4
1.2
—
—
—
0
0
5
15
3.34
1.52
1.2
1.1
—
—
—
0
0
110
889
1.26
1.49
1.7
1.8
1.5
1.6
%
0.43
93
749
1060
10308
1.20
1.45
24.6
9.3
25.3
25.5
u/l
0.12
1042
9826
11
52
2.13
1.44
1.2
1.1
—
—
—
0
0
9
40
2.26
1.40
1.3
1.1
—
—
—
0
0
80
627
1.30
1.39
5.8
8.4
0.7
0.7
%
0.32
80
622
129
1073
1.23
1.36
3.8
3.2
279.3
231.9
ng/l
0.47
118
983
5
17
2.95
1.36
1.0
2.1
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
9
43
2.10
1.30
1.3
1.1
—
—
—
0
0
19
114
1.68
1.28
2.7
3.5
—
—
—
0
0
27
178
1.53
1.27
2.2
1.9
188.8
214.6
pmol/l
0.48
27
167
19
115
1.66
1.25
1.1
1.0
1.5
1.5
g/l
0.18
19
99
11
58
1.90
1.12
1.5
1.3
0.9
1.0
g/l
0.48
11
58
23
152
1.52
1.09
1.0
1.1
—
—
—
0
0
966
9382
1.14
1.08
6.8
6.5
38.6
40.8
mmol/mol
12.27
925
8605
39
288
1.37
1.06
1.2
1.9
—
—
—
0
0
5
22
2.28
1.03
1.4
1.5
—
—
—
0
0
7
34
2.06
1.03
1.1
1.1
—
—
—
0
0
0
31
0.00
0.96
0.0
1.3
—
116.3
—
0
26
153
1342
1.16
0.94
5.0
4.9
31.0
33.0
%
1.82
125
867
32
235
1.37
0.92
1.1
1.2
—
3.3
—
0
25
19
127
1.50
0.89
1.7
1.3
—
—
—
0
0
10
56
1.79
0.88
1.3
7.0
—
72.2
—
0
17
8
45
1.78
0.84
1.1
1.3
—
—
—
0
0
64
525
1.23
0.84
2.9
2.3
1.3
1.2
%
0.47
64
520
6
32
1.88
0.82
5.7
2.8
—
—
—
0
0
6
32
1.88
0.82
5.7
2.8
—
—
—
0
0
8
47
1.71
0.80
3.4
2.2
65.2
51.3
umol/l
—
8
34
24
174
1.39
0.77
1.1
1.2
—
49.2
—
0
19
1015
9945
1.12
0.77
6.3
5.4
2.3
2.6
mmol/l
39.26
968
9032
0
28
0.00
0.76
0.0
2.6
—
8.7
—
0
13
17
244
0.69
0.76
1.5
1.5
—
—
—
0
0
9
54
1.67
0.74
2.1
1.5
2.4
3.2
u/field
—
9
42
33
254
1.31
0.74
1.1
1.2
—
32.8
—
0
12
9
56
1.61
0.72
1.3
2.3
—
—
—
0
0
7
40
1.75
0.71
7.7
7.9
65.1
74.7
%
—
7
35
5
26
1.93
0.70
1.2
1.1
—
—
—
0
0
28
212
1.33
0.70
2.1
1.3
—
—
—
0
0
5
27
1.86
0.68
1.4
1.1
—
—
—
0
0
5
27
1.86
0.68
1.4
1.1
—
—
—
0
0
400
3784
1.08
0.67
4.6
3.9
2.0
2.0
ug/l
0.04
360
3371
8
127
0.63
0.64
2.4
1.9
—
—
—
0
0
5
29
1.73
0.64
1.6
1.1
—
—
—
0
0
5
29
1.73
0.64
1.6
1.1
—
—
—
0
0
8
49
1.64
0.62
1.0
1.0
—
—
—
0
0
60
513
1.18
0.57
2.8
2.3
0.7
0.7
%
0.39
60
489
6
36
1.67
0.56
1.8
1.4
—
—
—
0
0
6
36
1.67
0.56
1.2
1.2
221.9
248.6
iu/ml
—
6
36
9
61
1.48
0.53
1.1
1.1
—
—
—
0
0
9
61
1.48
0.53
1.1
1.1
—
—
—
0
0
9
62
1.45
0.53
1.1
1.1
—
—
—
0
0
9
62
1.45
0.53
1.1
1.1
—
—
—
0
0
9
62
1.45
0.53
1.1
1.1
—
—
—
0
0
198
2128
0.92
0.52
2.8
2.7
0.8
0.7
ug/l
0.07
140
1434
211
2261
0.92
0.51
4.9
4.2
1.0
1.0
kg/l
0.08
39
334
32
390
0.82
0.50
1.5
1.6
—
—
—
0
0
107
967
1.12
0.49
1.3
1.4
—
—
—
0
0
7
110
0.63
0.48
2.4
1.8
—
—
—
0
0
162
1501
1.09
0.46
1.2
1.2
8.1
12.8
u/ml
0.54
62
541
11
77
1.43
0.45
1.0
1.1
—
—
—
0
0
333
3487
0.94
0.44
3.2
3.2
7.0
7.3
mmol/l
0.45
274
2915
120
1099
1.10
0.44
2.1
2.5
4.7
7.5
ug/l
2.34
87
958
15
113
1.33
0.42
1.1
1.1
—
20.6
—
0
5
8
61
1.31
0.39
1.0
1.7
9.8
14.0
umol/l
—
8
55
196
1847
1.07
0.38
1.3
1.2
0.7
1.7
u/ml
2.86
39
482
32
272
1.18
0.36
1.3
1.1
—
—
—
0
0
6
42
1.43
0.35
1.2
1.2
—
—
—
0
0
5
80
0.62
0.35
1.4
1.5
—
56.7
—
0
6
15
189
0.79
0.34
1.4
1.4
—
—
—
0
0
30
256
1.18
0.33
1.5
1.4
316.3
300.1
ug/g
0.14
16
148
32
275
1.17
0.33
1.3
1.1
—
—
—
0
0
17
137
1.24
0.32
2.3
1.7
270.2
269.7
mu/l
0.00
17
127
26
220
1.19
0.32
1.7
1.4
—
—
—
0
0
26
220
1.19
0.32
1.7
1.4
—
—
—
0
0
10
75
1.34
0.30
1.1
1.0
302.0
283.7
mg/l
—
10
67
34
297
1.15
0.29
2.7
2.3
226.8
65.8
ug/min
0.62
20
184
984
9740
1.05
0.28
5.4
5.0
6.0
6.1
mmol/l
0.61
910
8744
28
244
1.15
0.26
1.6
1.6
—
—
—
0
0
6
82
0.73
0.24
1.3
1.5
—
224.5
—
0
11
59
543
1.09
0.23
1.3
1.3
—
49.4
—
0
20
10
79
1.27
0.22
1.0
1.1
—
5.4
—
0
5
0
11
0.00
0.21
0.0
1.6
—
22.6
—
0
5
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.7
—
—
—
0
0
1072
10654
1.05
0.20
52.2
20.1
374.9
243.0
e9/l
98.24
1055
10285
1072
10657
1.04
0.19
52.1
20.2
4.8
4.5
e12/l
26.26
1049
10246
32
353
0.90
0.19
1.5
1.5
—
—
—
0
0
1072
10658
1.04
0.18
52.2
20.2
10.2
6.8
e9/l
26.40
1051
10251
1072
10659
1.04
0.18
52.4
20.3
135.1
135.4
g/l
0.19
1062
10434
7
59
1.19
0.18
1.3
1.4
7.4
6.3
u/l
—
7
52
11
91
1.21
0.17
2.5
2.1
5.3
2.2
u/field
—
6
35
5
68
0.73
0.17
2.4
2.1
—
144.5
—
0
17
12
101
1.19
0.16
2.4
2.5
640.6
621.4
ml
—
7
70
32
292
1.10
0.16
1.3
1.3
—
—
—
0
0
41
379
1.08
0.16
1.0
1.1
—
—
—
0
0
246
2400
1.03
0.15
1.7
1.7
56614269.5
19322115.5
pmol/l
0.29
189
1946
7
86
0.81
0.14
1.1
1.6
—
28.2
—
0
19
138
1427
0.96
0.14
9.1
7.2
—
—
—
0
0
159
1543
1.03
0.13
1.3
1.3
22.1
38.2
iu/ml
2.13
56
484
355
3611
0.98
0.13
4.0
4.0
16.6
8.1
mg/mmol
1.22
227
2254
40
376
1.07
0.11
1.3
1.2
—
—
—
0
0
268
2729
0.98
0.11
1.6
1.6
1.5
1.4
mmol/l
1.90
229
2247
52
495
1.05
0.10
1.2
1.2
105.1
126.0
iu/ml
0.18
19
195
5
44
1.14
0.10
1.4
1.4
—
—
—
0
0
18
164
1.10
0.09
1.6
1.4
—
—
—
0
0
10
87
1.15
0.09
1.0
1.1
—
73.2
—
0
10
6
57
1.05
0.08
1.2
1.2
—
—
—
0
0
6
57
1.05
0.08
1.2
1.2
—
—
—
0
0
301
3049
0.98
0.08
3.8
3.8
20.7
24.2
%
4.10
136
1457
6
70
0.86
0.07
1.5
1.2
0.6
1.7
u/ml
—
6
42
12
132
0.91
0.06
1.2
1.4
—
—
—
0
0
19
197
0.96
0.01
1.3
1.8
3.9
4.8
iu/l
—
8
61
21
209
1.00
0.00
1.2
1.3
97.4
798.8
e6/l
0.79
14
178
21
209
1.00
0.00
1.1
1.3
1.3
46.2
e6/l
0.98
12
171
23
231
1.00
0.00
7.0
3.5
22.0
27.7
mg/l
0.42
15
155
26
265
0.98
0.00
1.4
1.6
13627.4
12686.0
e6/l
0.05
18
194
5
51
0.98
0.00
1.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
12.0
—
0
6
0
7
0.00
0.00
0.0
1.1
—
111.3
—
0
7
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
19.6
—
0
5
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
6
69
0.87
0.00
1.5
1.2
2.1
2.0
mmol/l
—
6
64
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint POLYCYTVERA and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| POLYCYTVERA | 2.079 [1.84, 2.35] | < 0.001 |
| Birth year | 0.99 [0.98, 1.0] | 0.027 |
During the follow-up period (1.1.1998 — 31.12.2019), 1275 out of 3089 females with POLYCYTVERA died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| POLYCYTVERA | 1.913 [1.67, 2.19] | < 0.001 |
| Birth year | 0.986 [0.98, 0.99] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 1129 out of 2970 males with POLYCYTVERA died.
Mortality risk
Mortality risk for people of age
years, who have POLYCYTVERA.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.135% | 0.366% |
| 5 | 0.975% | 2.055% |
| 10 | 2.376% | 5.434% |
| 15 | 4.47% | 10.324% |
| 20 | 8.094% | 16.756% |
Relationships between endpoints
↥Index endpoint: POLYCYTVERA – Polycythaemia vera
GWS hits: 12
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data